- RecruitingPHASE3
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
This study is testing if combining two targeted therapies, belzutifan and zanzalintinib, works better than belzutifan alone for advanced kidney cancer. Researchers want to see if this combination helps people live longer and keeps the cancer from getting worse.
For: Carcinoma, Renal CellArgentina · Australia · Brazil - RecruitingPHASE3
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
This study looks at the long-term effects of a medicine called belzutifan for people with advanced cancers or cancers linked to Von Hippel-Lindau disease. It's for those already taking belzutifan in other trials. The aim is to see how long people live after starting this treatment.
For: Von Hippel-Lindau Disease · Malignant NeoplasmsUnited States · Australia · Belgium - RecruitingPHASE2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This study is testing a new medicine called belzutifan for certain types of advanced cancers, including rare adrenal gland, gut, and kidney cancers. We want to see how well it works and if it's safe for people aged 12 and over.
For: Pheochromocytoma/Paraganglioma · Pancreatic Neuroendocrine Tumor · Von Hippel-Lindau DiseaseUnited States · Australia · Canada - RecruitingPHASE1, PHASE2
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
This study looks at new drug combinations for kidney cancer (renal cell carcinoma) that has come back after previous treatment. It aims to find out if these combinations are safe and effective. It's for people aged 18-120 with this specific type of kidney cancer.
For: Renal Cell CarcinomaUnited States · Chile · France - Active not recruitingPHASE2
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
This study is testing a new combination treatment for advanced breast cancer. It combines a drug called belzutifan with fulvestrant, comparing it to standard hormone therapy. The goal is to see if this new approach is effective and safe for people whose cancer has spread and is hormone-sensitive.
For: Metastatic Breast CancerUnited States · Argentina · Canada - RecruitingPHASE3
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
This study is looking for better ways to treat advanced kidney cancer that has come back after earlier treatment. Researchers want to see if a new combination of medicines, belzutifan and zanzalintinib, works better than a standard medicine, cabozantinib, at shrinking the cancer.
For: Renal Cell CarcinomaArgentina · Australia · Austria - Active not recruitingPHASE1, PHASE2
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
This study is looking at new combinations of medicines for kidney cancer (renal cell carcinoma) that has spread or come back. We want to see how safe and effective these new treatments are. It's an early-stage study to find the best way to use these combinations.
For: Carcinoma, Renal CellUnited States · Australia · Canada - Active not recruitingPHASE3
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
This study is comparing two treatments, belzutifan plus pembrolizumab, against pembrolizumab alone, for kidney cancer that has been removed. It aims to see if the combination treatment can prevent the cancer from returning.
For: Carcinoma, Renal CellUnited States · Australia · Brazil - Active not recruitingPHASE2
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
This study looks at a new drug called belzutifan for advanced kidney cancer. We want to see if a higher dose works better and is safe for people whose cancer has grown despite previous treatments.
For: Carcinoma, Renal CellUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
This study is testing new combinations of medicines for advanced kidney cancer (renal cell carcinoma). Its aim is to see if these new combinations work better and are safe compared to a standard treatment, for people who haven't had treatment for their advanced cancer before.
For: Carcinoma, Renal CellUnited States · Australia · Brazil - Active not recruitingPHASE3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
This study compares two treatments for advanced kidney cancer: a combination of belzutifan and lenvatinib, versus cabozantinib. It's for people whose cancer has grown even after previous treatment, aiming to find which option works better and is safer.
For: Carcinoma, Renal CellUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
This study looks at new drug combinations for advanced kidney cancer that has not responded to previous treatments. It aims to see how safe and effective these new combinations are.
For: Carcinoma, Renal CellUnited States · Australia · Canada - Active not recruitingPHASE3
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
This study compares a new drug called belzutifan with an existing drug, everolimus, for people with advanced kidney cancer. We want to see if belzutifan can stop the cancer from growing for longer and help people live longer than everolimus.
For: Carcinoma, Renal CellUnited States · Brazil · Canada - Active not recruitingPHASE2
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
This study is testing a new medicine called belzutifan for people with Von Hippel-Lindau (VHL) disease who have kidney cancer. It aims to see how well the medicine works and if it's safe to use. Patients will take the medicine continuously and have regular scans to check their progress.
For: VHL - Von Hippel-Lindau Syndrome · VHL Gene Mutation · VHL SyndromeUnited States · Denmark · France - RecruitingPHASE2
An Experimental Study of Belzutifan Impact on Catecholamine Metabolism
This study looks at how a drug called Belzutifan affects chemicals (adrenaline and noradrenaline) in people with a rare growth condition called pheochromocytoma or paraganglioma. We want to see if the drug changes how these chemicals are made and processed in the body over five days.
For: Pheochromocytoma and Paraganglioma (PPGL) · Pheochromocytoma Malignant · Pheochromocytoma, MetastaticUnited Kingdom